A GSH-activatable ruthenium(<scp>ii</scp>)-azo photosensitizer for two-photon photodynamic therapy

Zeng, Leli; Kuang, Shi; Li, Guanying; Jin, Chengzhi; Ji, Liang‐Nian; Chao, Hui

doi:10.1039/c6cc10330h

Cited by 101 publications

(73 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Chao’s group utilized a GSH-activatable Ru(II)-azo photosensitizer, ( 15b ), for two-photon PDT. 265 15b did not show luminescence but exhibited a strong luminescence after incubation in HeLa cells due to the activation of intracellular GSH. 15b accumulated to a significant extent in mitochondria and could produce ROS in HeLa cells upon two-photon irradiation (810 nm, 100 mW).…”

Section: Ruthenium(ii) Polypyridyl Complexesmentioning

confidence: 94%

See 1 more Smart Citation

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

Self Cite

View full text Add to dashboard Cite

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. The ruthenium(III) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(II) complexes have also attracted significant attention as anticancer candidates; however, only few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(II) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(II)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(II) complexes, their targeted delivery, and their activity in nanomaterial systems.

show abstract

Section: Ruthenium(ii) Polypyridyl Complexesmentioning

confidence: 94%

“…In contrast, 15b was significantly cytotoxic in MCTSs, with an IC 50 value as low as 5.71 μM upon two-photon irradiation. 265 The Chao et al study demonstrated that the combination of organelle-targeting and two-photon activation provides a valuable paradigm for developing Ru(II) complexes for PDT applications.…”

Section: Ruthenium(ii) Polypyridyl Complexesmentioning

confidence: 99%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…[83] More recently, the group of Choi showedt hat an azo-based binuclear ruthenium(II) complex, Ru-azo, could also be used as as mart photosensitizer in two-photon photodynamic anticancer therapy( Figure17b). [84] Indeed, this complex showed high accumulation in the mitochondria of cancer cells and produced efficient photocytotoxicity upon bioreductive activation by GSH and two-photon excitation at l = 810 nm.…”

Section: Fluorescence Activation Throughreductive Cleavage Of the Azomentioning

confidence: 99%

“…As a highly relevant application, azo‐based iridium(III) complexes (IrX) have been used as multicolor phosphorescent probes to detect hypoxia in both adherent living cells and oxygen‐gradient 3D multicellular spheroids at depths of over 100 μm, which have many similarities to the in vivo environment (Figure d) . More recently, the group of Choi showed that an azo‐based binuclear ruthenium(II) complex, Ru–azo, could also be used as a smart photosensitizer in two‐photon photodynamic anticancer therapy (Figure b) . Indeed, this complex showed high accumulation in the mitochondria of cancer cells and produced efficient photocytotoxicity upon bioreductive activation by GSH and two‐photon excitation at λ =810 nm.…”

Section: Azo‐based Fluorogenic Probesmentioning

confidence: 99%

Azo‐Based Fluorogenic Probes for Biosensing and Bioimaging: Recent Advances and Upcoming Challenges

Chevalier

Renard

Romieu

2017

Chemistry An Asian Journal

View full text Add to dashboard Cite

The use of nonfluorescent azo dyes as dark quenchers in activatable optical bioprobes based on the Förster resonance energy transfer (FRET) mechanism and designed to target a wide range of enzymes has been established for over two decades. The key value of the azo moiety (-N=N-) to act as an efficient "ON-OFF" switch of fluorescence once introduced within the core structure of conventional organic-based fluorophores (mainly fluorescent aniline derivatives) has recently been exploited in the development of alternative reaction-based small-molecule probes based on the "profluorescence" concept. These unprecedented "azobenzene-caged" fluorophores are valuable tools for the detection of a wide range of reactive (bio)analytes. This review highlights the most recent and relevant advances made in the design and biosensing/bioimaging applications of azo-based fluorogenic probes. Emphasis is also placed on relevant achievements in the synthesis of bioconjugatable/biocompatible azo dyes used as starting building blocks in the rational and rapid construction of these fluorescent chemodosimeters. Finally, a brief glimpse of possible future biomedical applications (theranostics) of these "smart" azobenzene-based molecular systems is presented.

show abstract

“…GSH is a necessary molecule for the adjusting of oxidation‐reduction state in living subjects . Recently, Fan and co‐workers developed a cyanine derivative‐based nanoprobe (IR806‐PDA) for in vivo PAD of GSH .…”

Section: Applications Of Photoacoustic Detectionmentioning

confidence: 99%

Photoacoustic Probes for Molecular Detection: Recent Advances and Perspectives

Zeng

Lin

et al. 2018

Small

Self Cite

View full text Add to dashboard Cite

Photoacoustic (PA) imaging (PAI) is a noninvasive and nonionizing biomedical imaging modality that combines the advantages of optical imaging and ultrasound imaging. Based on PAI, photoacoustic detection (PAD) is an emerging approach that is involved with the interaction between PA probes and analytes resulting in the changes of photoacoustic signals for molecular detection with rich contrast, high resolution, and deep tissue penetration. This Review focuses on the recent development of PA probes in PAD. The following contents will be discussed in detail: 1) the construction of PA probes; 2) the applications and mechanisms of PAD to different types of analytes, including microenvironments, small biomolecules, or metal ions; 3) the challenges and perspectives of PA probes in PAD.

show abstract

A GSH-activatable ruthenium(ii)-azo photosensitizer for two-photon photodynamic therapy

Cited by 101 publications

References 45 publications

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Azo‐Based Fluorogenic Probes for Biosensing and Bioimaging: Recent Advances and Upcoming Challenges

Photoacoustic Probes for Molecular Detection: Recent Advances and Perspectives

Contact Info

Product

Resources

About